Infant Vaccines (Respiratory Syncytial Virus)

RSV usually causes mild, cold-like symptoms, but it can lead to serious illness such as severe lung infections, including bronchiolitis and pneumonia. Learn More

Phase: III

Time frame: 17 months

Age requirements:  1 years or less

Compensation: up to $1,250 for patient

Key Inclusion Criteria:

  • Healthy infants in their first year of life and born ≥ 35 weeks 0 days GA
  • Infants who are entering their first RSV season at the time of screening
  • Subject is available to complete the follow- up period, which will be 17 months after receipt of study drug.
  • Subject and parent/ guardian are able to attend all scheduled visits and to comply with all trial procedures.


Additional Criteria:
At screening visit, additional criteria will be reviewed to determine eligibility for the study. Qualified participants will receive study medication, medical care and compensation for the time and travel of each completed study visit.

Back to list


Thank you for your interest in our studies. Please use the following form to begin your enrollment process in a clinical trial or to join our database of opted-in patients. You will receive notification via email and/or regular mail about new clinical trial opportunities.

Fields marked with an asterisk (*) are required.

I am interested in the following studies:

By completing this form, you are not committing to participate in a clinical research study or being selected as a study participant. You will be given the option to select whether or not you'd like to be considered for potential participation.